Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.59 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.56 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624979 | 0.83 | EPHX2 (0.66) | EPHX2CYP2C9CYP2C19CYP2J2DGAT1 | |
| SCHEMBL4251142 | 0.82 | EPHX2 (0.67) | EPHX2CYP2C9CYP2C19CYP2J2DGAT1 | |
| SCHEMBL13702303 | 0.81 | L3MBTL1 (0.65) | EPHX2CYP2C9CYP2C19CYP2J2GABRA5 | |
| SCHEMBL4178518 | 0.81 | EPHX2 (0.73) | EPHX2CYP2C9CYP2C19CYP2J2DGAT1 | |
| Hydrochloric Acid SCHEMBL4253231 | 0.81 | EPHX2 (0.66) | EPHX2CYP2C9CYP2C19CYP2J2DGAT1 | |
| SCHEMBL20289570 | 0.80 | MEN1 (0.57) | GABRA5DGAT1L3MBTL1 | |
| SCHEMBL4298673 | 0.79 | DGAT1 (0.72) | EPHX2CYP2C9CYP2C19CYP2J2GABRA5 | |
| SCHEMBL26494561 | 0.79 | GABRA5 (0.51) | GABRA5DGAT1MAPT | |
| SCHEMBL13701755 | 0.79 | L3MBTL1 (0.65) | EPHX2CYP2C9CYP2C19CYP2J2GABRA5 | |
| SCHEMBL31498883 | 0.79 | L3MBTL1 (0.65) | EPHX2CYP2C9CYP2C19CYP2J2DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286791-A1 | Amide Compounds | DLAT, DGAT2, DGAT1 | EPHX2 1912/4885CYP2C9 2594/4885CYP2C19 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.